Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.75 |
| ▸ | CA9 | Q16790 | 2/20 | 0.75 |
| ▸ | CA6 | P23280 | 1/20 | 0.75 |
| ▸ | CA5A | P35218 | 1/20 | 0.75 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1560310 | 0.94 | CA1 (0.86) | CA1CA9CA6CA5ACA5B | |
| Hydrochloric Acid SCHEMBL5392985 | 0.94 | — | — | |
| SCHEMBL121695 | 0.94 | — | — | |
| SCHEMBL5382582 | 0.94 | — | — | |
| Hydrochloric Acid SCHEMBL6756265 | 0.89 | CA1 (0.60) | CA1CA9CA6CA5ACA5B | |
| SCHEMBL15864274 | 0.88 | CA1 (0.75) | CA1CA9CA6CA5ACA5B | |
| SCHEMBL3243495 | 0.88 | CA1 (0.75) | CA1CA9CA6CA5ACA5B | |
| SCHEMBL16703451 | 0.88 | — | — | |
| SCHEMBL15864291 | 0.88 | CA1 (0.75) | CA1CA9CA6CA5ACA5B | |
| Hydrogen Sulfide SCHEMBL1276869 | 0.88 | CA1 (0.75) | CA1CA9CA6CA5ACA5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0317855-B1 | PHARMACEUTICAL PRODUCTS | Beiersdorf Aktiengesellschaft (DE) | 1991-12-18 | — | — | EP | claimed |
| US-20240011977-A1 | TISSUE PROCESSING | APPLIKATE TECHNOLOGIES, INC. | 2024-01-11 | — | — | US | disclosed |
| US-20230151415-A1 | METHODS FOR DETECTING TARGET NUCLEIC ACIDS BY IN SITU HYBRIDIZATION AND A KIT THEREOF | ADVANCED CELL DIAGNOSTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| CN-115768780-A | Method for detecting target nucleic acid by in situ hybridization and kit therefor | 领先细胞医疗诊断有限公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-4132942-A1 | IN SITU METHODS FOR DETECTING TARGET NUCLEIC ACIDS BYHYBRIDIZATION AND A KIT THEREOF | Advanced Cell Diagnostics, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11573179-B2 | Tissue processing | APPLIKATE TECHNOLOGIES LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210072156-A1 | TISSUE PROCESSING | APPLIKATE TECHNOLOGIES, INC. | 2021-03-11 | — | — | US | disclosed |
| WO-2021035211-A1 | TISSUE PROCESSING | APPLIKATE TECHNOLOGIES LLC (US) | 2021-02-25 | — | — | WO | disclosed |
| US-10591392-B2 | Simultaneous dehydration and staining of tissue for deep imaging | APPLIKATE TECHNOLOGIES LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-9625359-B2 | Tissue sample preparation, and MALDI MS imaging thereof | BRANDEIS UNIVERSITY (US) | 2017-04-18 | — | — | US | disclosed |
| US-8945941-B2 | Tissue sample preparation and MALDI MS imaging thereof | BRANDEIS UNIVERSITY (US) | 2015-02-03 | — | — | US | disclosed |
| US-20090325222-A1 | Tissue Sample Preparation and MALDI MS Imaging Thereof | BRANDEIS UNIVERSITY (US) | 2009-12-31 | — | — | US | disclosed |
| US-5294644-A | Nonionic surfactants for solubility | ISP INVESTMENTS INC. (US) | 1994-03-15 | — | — | US | disclosed |
| US-5093031-A | Surface active lactams | ISP INVESTMENTS INC. (US) | 1992-03-03 | — | — | US | disclosed |
| EP-0311632-A4 | SURFACE ACTIVE LACTAMS | — | 1990-12-27 | — | — | EP | disclosed |
| EP-0311632-A1 | SURFACE ACTIVE LACTAMS. | GAF CORP (US) | 1989-04-19 | — | — | EP | disclosed |
| WO-1988000184-A1 | SURFACE ACTIVE LACTAMS | GAF CORPORATION (US) | 1988-01-14 | — | — | WO | disclosed |
| US-4547498-A | BLEND OF TRIAMTERENE AND HYDROCHLOROTHIAZIDE-PREVENTION OF HYPOKALEMIC/BLOOD/METAL CONCENTRATIONS | MYLAN PHARMACEUTICALS INC. (US) | 1985-10-15 | — | — | US | disclosed |
| US-4526777-A | Finely dividing active ingredients, separately mixing each with carriers, compacting, comminuting, blending | MYLAN PHARMACEUTICALS INC. (US) | 1985-07-02 | — | — | US | disclosed |
| US-4387099-A | Alkanolamine derivatives | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1983-06-07 | — | — | US | disclosed |